Magnesium sulphate (MgSO 4 ) given to women in preterm labor reduces cerebral palsy in their offspring but the mechanism behind this protection is unclear, limiting its effective, safe clinical implementation. Previous studies suggest that MgSO 4 is not neuroprotective if administered during or after the insult, so we hypothesised that MgSO 4 induces preconditioning in the immature brain. Therefore, we administered MgSO 4 at various time-points before/after unilateral hypoxia-ischemia (HI) in seven-day-old rats. We found that MgSO 4 treatment administered as a bolus between 6 days and 12 h prior to HI markedly reduced the brain injury, with maximal protection achieved by 1.1 mg/g MgSO 4 administered 24 h before HI. As serum magnesium levels returned to baseline before the induction of HI, we ascribed this reduction in brain injury to preconditioning. Cerebral blood flow was unaffected, but mRNAs/miRNAs involved in mitochondrial function and metabolism were modulated by MgSO 4 . Metabolomic analysis (H þ -NMR) disclosed that MgSO 4 attenuated HI-induced increases in succinate and prevented depletion of high-energy phosphates. MgSO 4 pretreatment preserved mitochondrial respiration, reducing ROS production and inflammation after HI. Therefore, we propose that MgSO 4 evokes preconditioning via induction of mitochondrial resistance and attenuation of inflammation.
Introduction
Perinatal brain injury in term and preterm infants remains a paramount clinical problem causing death and neurological disabilities. 1, 2 Approximately 30% of infants born preterm (<28 gestational weeks) will suffer from cerebral palsy (CP), cognitive impairment or neuropsychiatric disorders. [3] [4] [5] CP is the most common cause of severe disability in children (2/1000 births) and a major cost to sufferers, their families and society, 6, 7 underscoring the need for development of treatment and preventive strategies.
Magnesium administered as magnesium sulphate (MgSO 4 ) has neuroprotective properties. Clinical cohort studies demonstrated that offspring of mothers treated with antenatal MgSO 4 (given to inhibit preterm labor or as seizure prophylaxis in preeclampsia) had a lower risk of developing CP 8 and intraventricular/ periventricular hemorrhage. 9 Randomized controlled trials have subsequently confirmed these results [10] [11] [12] and a meta-analysis showed that the rate of CP or moderate/severe motor disability is reduced 30% by antenatal MgSO 4 . 13 Additionally, recent discoveries demonstrate that the rates of echolucent/echodense brain lesions, 14 as well as cerebellar hemorrhages, 15 were attenuated. However, the mechanisms behind this protective effect remain obscure and the optimal dose for neuroprotection in preterm fetuses/neonates without serious side effects is unknown. Preconditioning is a phenomenon whereby subthreshold exposure or chemical agents confer resistance to a subsequent severe insult. 16 The immature brain is responsive to a number of preconditioning exposures, e.g. sub-threshold hypoxia 17, 18 or pre-exposure to pharmacological agents such as xenon 19 which reduce hypoxic-ischemic (HI) brain injury substantially. Clinically, MgSO 4 is given antenatally to mothers in preterm labor well in advance of the expected critical period for development of brain injury. Indeed, the issue of timing is critical as there is no evidence of efficacy when MgSO 4 is administered immediately before, during or after the insult. [20] [21] [22] Here we investigate our hypothesis that MgSO 4 induces preconditioning, thereby providing tolerance to insults such as HI or excitotoxicity occurring during the early neonatal period, and define the mechanisms underlying its neuroprotective effect. A better understanding of the mechanisms behind the neuroprotective actions of MgSO 4 will optimize the efficacy and safety of treatment in preterms and widen its potential therapeutic applications in high-risk pregnancies to prevent asphyxial brain injury or prior to open heart surgery in neonates.
Materials and methods

Experimental design
Prior to data acquisition, a power analysis was performed for calculation of appropriate sample size for reliable measurements. Final endpoints/rules for stopping data collection were set in advance and all experiments, including potential outliers, were included. Pups were randomly allocated to different groups from a variety of litters to avoid litter-specific outcome and marked numerically rather than according to individual treatment. During analysis, samples for microtubuleassociated protein-2 (MAP-2) and myelin basic protein (MBP), analyzed for serum Mg 2þ content, proton nuclear magnetic resonance (H þ -NMR), mRNA/ miRNA, mitochondrial respiration, reactive oxygen species (ROS) formation, Bio Plex and cerebral blood flow (CBF) measurements were completely blinded to the researchers through numerical sample-marking with the researchers unaware of group belonging in order to avoid bias. Male and female Wistar rat pups from in house breeding at the facility of Experimental Biomedicine (EBM) were used along with Swiss mice from the Robert Debre hospital rodent facility. Animal experimental procedures conformed to guidelines established by the Swedish Board of Agriculture (SJVFS 2015: 38) , were approved by the Gothenburg Animal Ethics Committee (ethical license 333-2012, 138-2013 and 01-2016) or by the Bichat-Robert Debre committee (ethical license 2011-14/646-048) and are reported in a manner consistent with the ARRIVE (Animal Research: Reporting in Vivo Experiments) guidelines. Animals were housed at EBM or at the Robert Debre hospital with access to food and water ad libitum. Mortality was low and not different between groups.
Preconditioning
Wistar rats were randomized into two groups and injected intraperitoneally (i.p.) with an MgSO 4 bolus (Magnesium sulphate, 1 mmol/ml, Addex; Fresenius Kabi, Halden, Norway) (1.1 mg/g (n ¼ 245), 0.55 mg/g (n ¼ 46) or 0.37 mg/g (n ¼ 41)) or as vehicle an equivalent volume of saline (Saline 9 mg/ml, B Braun Melsungen AG, Melsungen, Germany) prior to the induction of HI. The optimal dose (1.1 mg/g) was injected at different time-points prior to (six days (n ¼ 43), 72 h (n ¼ 36), 24 h (n ¼ 41), 12 h (n ¼ 33), 3 h (n ¼ 35) and 30 min (n ¼ 33)) or post (1 h (n ¼ 31) HI. Brain injury was evaluated by macroscopic scoring and immunohistochemical staining seven days after HI.
Hypoxia-ischemia
At PND 7, pups were exposed to HI as previously described. 23, 24 Rats were anesthetized (isoflurane 1.5-5%) (IsoFlo vet 100%; Abbott Laboratories Ltd, Illinois, USA) in 1:1 oxygen-nitrogen mixture. The left common carotid artery was ligated with a 6.0 silk suture (Seide; Vo¨mel, Germany), the incision closed and infiltrated with a local anesthetic (Xylocain 20 mg/ml, lidocain, hydrochloride; Astra Zeneca, So¨derta¨lje, Sweden). The total duration was <5 min. Pups were returned to their dams for recovery (1 h), then placed in a humidified chamber with air for 10 min, followed by 60 min hypoxia (8% oxygen in nitrogen), and 10 min in air (36 C).
Tissue collection and processing
On PND 14, rats were deeply anesthetized (0.1 ml of thiopental, Pentocur, Thiopental, 50 mg/ml i.p.; Abcur AB, Helsingborg, Sweden) and killed for histological processing; brains were fixed by transcardial perfusion (6% paraformaldehyde, Histofix; Histolab, Gothenburg, Sweden). Once dissected out, brains were photographed and graded macroscopically according to a previously published protocol 25 (Table  S1 ). After dehydration, brains were paraffin-embedded and cut (Meditome A550) into 7 mm thick sections at $3.3 mm from bregma. 26 
Immunohistochemistry
Sections were prepared for immunohistochemical staining by deparaffination in xylene followed by graded alcohol rehydration and boiling in 0.01 M citric acid buffer (pH 6.0) for antigen recovery followed by blocking of endogenous peroxidase/nonspecific binding (3% H 2 O 2 ). Sections were incubated overnight with primary antibody: Mouse anti-MAP-2 (1:1000; M4403 SigmaAldrich, St. Louis, Missouri, USA) or Mouse anti-MBP (1:10,000; SMI-94 Covance, Princeton, New Jersey, USA), washed and incubated in appropriate secondary antibody. ABC elite was used for visualization of immunoreactivity followed by submersion into 0.5 mg/ml 3.3-diaminobenzidine, NiSO 4 .
Brain injury evaluation
Brain injury was quantified as area loss of MAP-2 immunoreactivity at the level of anterior hippocampus. Total MAP-2 positive area was measured in each hemisphere (MicroImage, 4.0, Olympus Optical) and tissue loss calculated as MAP-2 positive area in the ipsilateral hemisphere subtracted from the contralateral. Loss of MBP was used immunohistochemically to determine white matter injury. The MBP positive staining was measured (MicroImage, 4.0, Olympus Optical) in both hemispheres and the proportion of white matter injury was calculated by comparing the ipsilateral hemisphere to the contralateral.
Serum Mg 2þ measurement
Pups (PND 6) were injected i.p. with MgSO 4 , (1.1 mg/g (n ¼ 17), 0.55 mg/g (n ¼ 13), 0.37 mg/g (n ¼ 14)) or vehicle (n ¼ 18) and decapitated after 3 or 24 h followed by immediate blood-collection. Serum was stored (À80 C) until analysis for Mg 2þ -content (Cobas 8000 Roche Diagnostics Scandinavia AB) by Centrallaboratoriet Klinisk Kemi, Sahlgrenska University Hospital, Gothenburg, Sweden.
RNA preparation
Pups (PND 6) were injected with MgSO 4 (1.1 mg/g) or vehicle and deeply anesthetized (0.1 ml of thiopental, sodium pentotal, 50 mg/ml i.p.) after 3 or 24 h (n ¼ 6/ group), perfused with saline (0.9% Sodium Chloride Solution) and brains collected, snap-frozen and stored in À80 C. Total RNA including miRNA was prepared from whole cortex samples using miRNeasy Mini Kit (Qiagen). The RNA quality, (RQI-scores) was 9-10 as checked with Experion RNA STDsense chip (Biorad). Purity and amount were determined using Nano Drop (260/280 ratio of 1.9 -2.1).
GeneChip expression analysis
Array expression analysis was performed according to the Affymetrix expression analysis technical manual, Genomics Centre, King's College London. Briefly, double-stranded cDNA was synthesized from total RNA and an in vitro transcription reaction was performed to produce biotin-labeled cRNA which was fragmented and hybridized to Affy mRNA array Gene ST v2.0, APT v1.15 (36,685 genes) and Affy miRNA 4.0. CEL files using the robust multi-array average algorithm 27 performing three distinct operations: global background normalization, across array normalization, and log2 transformation of perfect match values (http://stat-www.berkeley.edu/users/bolstad/RMAExpress/RMAExpress.html). The robust multi-array average analysis, data management, statistical analysis, and gene ontology was performed using GeneSifter (http://login.genesifter.net/) and IPA (https://analysis.ingenuity.com).
RT-PCR
cDNA was prepared from 1 mg RNA using QuantiTect Reverse Transcription Kit (Qiagen). Each PCR (20 lL) ((2 lL cDNA, 10 lL Quanti Fast SYBR Green PCR Master Mix (Qiagen) and 2 lL PCR primer (QuantiTech Primer Assay, Qiagen)), was run on a LightCycler 480 (Roche, Sweden) (Table S2) . Melting curve analysis ensured that only one PCR product was obtained and a standard curve generated using increasing concentrations of cDNA ensured quantification/ estimation amplification efficiency. Amplified transcripts were quantified using the relative standard curve and normalized against the reference gene Ywhaz. Results were expressed as ÁC q ; the difference in the quantification cycle (C q ) values between the target and reference genes. 28 The difference in ÁC q for the different samples was then directly compared.
Mitochondrial isolation
Pups (PND 6) were injected with MgSO 4 (1.1 mg/g) (n ¼ 34) or vehicle (n ¼ 37) and decapitated after 24 h (with or without HI). One hemisphere was immediately excised and homogenized in 3.8 ml 12% Percoll (GE Healthcare, Bio-Sciences AB, Uppsala, Sweden) in ice-cold MIB [225 mM mannitol, 75 mM sucrose, 1 mM EGTA, 5 mM HEPES-KOH, pH 7.2, 1 mg/mL fattyacid-free bovine serum albumin (BSA)] using a Dounce Homogenizer (7 ml, #432-1271, VWR). Homogenate was pipetted onto 3.5 ml 26% Percoll laying on 3.5 ml 40% Percoll in centrifuge tubes, subsequently centrifuged at 30,000g for 10 min (4 C). The mitochondrial fraction was moved to a 2 ml tube containing 1500 ml MIB (ratio 1:4) and centrifuged at 15,000g for 5 min (4 C). Pellets were washed in 1 ml MIB, centrifuged at 15,000g for 5 min (4 C) and resuspended in 75 ml MIB containing BSA 1 mg/ml.
High-resolution respirometry and O2k-fluorometry
The Oxygraph-2k (O2k, OROBOROS Instruments, Innsbruck, Austria) was used for measurements of respiration and combined with the Fluorescence-Sensor Green, O2k-Fluo LED2-Module for H 2 O 2 measurement. A protocol modified from our published methods 29 was used for mitochondrial respiration measurements in the O2k. Measurements were performed on mitochondria (25 C) in 2.1 mL MIR05 respiration buffer [20 mM HEPES, 10 mM KH 2 PO 4 , 110 mM sucrose, 20 mM taurine, 60 mM K-lactobionate, 0.5 mM EGTA, 3 mM MgCl 2 Á6H 2 O, 1 g/L BSA (fatty acid free)]. Pyruvate and malate (5 mM and 2.5 mM, respectively) or succinate (10 mM) with or without 0.5 mM Complex-I inhibitor rotenone (Rot) were used to determine Complex-I (CI) or Complex-II-(CII) linked LEAK respiration. ADP (f.c. 0.14 mM) was added which was saturating for oxygen flux to obtain oxidative phosphorylation (OXPHOS) capacity. FCCP (1 mM) was added to determine electron transfer system (ETS) capacity. Respiratory control ratio (RCR) was calculated as the ratio of the STATE 3 (ADP stimulated respiration of isolated coupled mitochondria in the presence of high ADP and P i concentrations) to the resting respiration rate STATE 4 (respiratory state obtained in isolated mitochondria when ADP has been maximally phosphorylated to ATP).
Mitochondrial ROS formation can be detected with an H 2 O 2 sensitive probe, here Amplex Õ UltraRed was used and a CII-linked protocol measuring respiration and H 2 O 2 flux simultaneously in the O2k-Fluorometer was applied. For further details see O2k-Fluorometry in Supplementary Materials.
For ROS production measurements, mitochondria were stimulated with ADP followed by rotenone, blocking Complex-I mediated respiration, allowing for the study of ROS produced solely at Complex-II driven by succinate addition. To induce maximal respiration/ROS production, FCCP (1 mM) was added. Volume-specific H 2 O 2 fluxes were calculated real-time (DatLab software, OROBOROS INSTRUMENTS, Innsbruck Austria). The stable portions of the H 2 O 2 fluxes were selected and artifacts induced by addition of substrates/chemicals were excluded. Values were normalized to total protein content.
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Metabolomics
Brains were collected at 3 h (n ¼ 10) or 24 h (n ¼ 10) following injection (PND 6) with MgSO 4 (1.1 mg/g) or vehicle (n ¼ 18); 24 h after injection with MgSO 4 (1.1 mg/g) (n ¼ 9) or vehicle (n ¼ 10), pups were exposed to HI (60 min) and brains collected immediately after hypoxia. Animals were decapitated and whole heads snap-frozen in À80 C isopenthane. Portions (10-30 mg) of parietal cortex were dissected out (À20 C) and solubilized in 3 mol/L HClO 4 33 (À10 C). After centrifugation at 5000g for 10 min, one volume of the supernatant was neutralized with 2.5 volumes of KHCO 3 (2 mol/L) and centrifuged to remove precipitated KHCO 3 . Blood was collected at decapitation and serum prepared as described above and saved in 2 ml Micro tubes (Sarstedt Aktiengesellshaft & Co, D-51588 Nu¨mbrecht) (À80 C). For detailed description of H þ -NMR protocol see Metabolomics in Supplementary Materials.
CBF
CBF was measured using the iodoantipyrine method 34 adapted for the immature rat. 35, 36 The measurements were performed in both hemispheres 24 h after MgSO 4 or vehicle administration without exposure to HI (no HI; vehicle n ¼ 11, MgSO 4 n ¼ 9), after 30 min of HI (30 min HI; vehicle n¼7, MgSO 4 n ¼ 8) and after 60 min of HI (60 min HI; vehicle n ¼ 9, MgSO 4 n ¼ 8). In all animals, 10 mCi, 100 ml 4-Iodo(N-metyl 14 C) antipyrine (ARC 0126A, ARC; USA) was subcutaneously injected in the neck followed by decapitation after 60 s. Blood, 10 ml, was collected directly and the hemispheres were dissected out, dissolved in Solveble TM (Perkin Elmer, Massachusetts; USA) and mixed with Ultima Gold TM (Perkin Elmer, Massachusetts; USA). Samples were measured in a Beta-counter, Tricarb 3810tr (Perkin Elmer, Massachusetts, USA) and calculated as previously described. 
Statistical measurements
All statistical analyses (except for gene expression and metabolomic analysis described above) were performed using Graph Pad Prism. Statistical significance was determined by nonparametric unpaired MannWhitney U-test, paired or unpaired two-tailed t-tests or ANOVA with or without Tukey's multiple comparisons test as specified in each figure legend (Mean AE SEM). P values < 0.05 were considered statistically significant. The number of sampled units, n, is stated for each experiment in the methodologic section.
Results
MgSO 4 pre-treatment reduces the extent of neonatal brain injury after HI
The effect of MgSO 4 on neonatal brain injury was first explored in a well-established model of HI in sevenday-old rats. 23 Macroscopic brain injury scoring (Table S1) showed that rats pre-treated with MgSO 4 (1.1 mg/g) 24 h prior to HI had markedly reduced brain damage 0.47 AE 0.14 (n ¼ 16) compared with 2.30 AE 0.18 (n ¼ 18) in pups pre-treated with saline (p < 0.0001) (Figure 1(a) and (c) ). Significant protection, was also seen when MgSO 4 was administered six days prior to HI ( 0.9 AE 0.2 (n ¼ 21) in MgSO 4 -treated pups vs. 1.9 AE 0.3 (n ¼ 20) in controls (p < 0.005)), three days prior to HI (1.7 AE 0.2 (n ¼ 18) in MgSO 4 -treated pups compared with 2.3 AE 0.2 (n ¼ 18) in controls (p < 0.05)) and 12 h prior to HI: 1.1 AE 0.2 (n ¼ 17) in MgSO 4 -treated pups vs. 2.3 AE 0.1 (n ¼ 16) in controls (p < 0.0001). The overall effect of MgSO 4 (1.1 mg/g) 6 days-12 h prior to HI is summarized in Figure 1 (b) (n ¼ 72/group). MgSO 4 had no significant effect on brain injury when administered 3 h or 30 min prior to or 1 h after HI (Figure 1(c) ). We also assessed the effect of MgSO 4 pre-treatment on the loss of grey matter using immunoreactivity for MAP-2 and found a significant reduction in tissue loss when MgSO 4 Figure 1 (a) and (c)).
There are exposures other than HI that are believed to elicit preterm brain injury so we evaluated the neuroprotective effect of MgSO 4 in a well-characterized excitotoxic model of preterm brain injury. 38 MgSO 4 (0.92 mg/g) 24 h prior to ibotenate injection (10 mg) reduced both grey and white matter injury ( Figure S1 ) supporting the concept that MgSO 4 offers efficacy in the treatment of immature brain injury regardless of its aetiology.
The neuroprotective dose of MgSO 4 induces preconditioning
As the optimal interval between MgSO 4 treatment and HI was 24 h, the next step was to identify the optimal dose required for maximal protection. We injected PND 6 rats with different doses of MgSO 4 (0.37 mg/g, 0.55 mg/g or 1.1 mg/g) 24 h prior to HI. Brains were analyzed as described above and we found that only a dose of 1.1 mg/g provided the animals with significant protection (Figure 2(a) ). We measured the concentration of Mg 2þ in serum samples from pups after receiving vehicle or MgSO 4 at 3 or 24 h after administration (Figure 2(b) ). For all doses tested, serum Mg 2þ levels increased transiently, peaking at 3 h after administration and returning to baseline within 24 h. Administration of the neuroprotective dose of MgSO 4 (1.1 mg/g) resulted in a peak Mg 2þ concentration of 3.3 AE 0.2 mmol/L at 3 h later which is within the therapeutic window (2-4 mmol/L) when MgSO 4 is given antenatally to women for seizure prophylaxis in preeclampsia or for neuroprotection. As pre-exposure with MgSO 4 protects the brain in spite of the levels of magnesium being within the physiological range during/ after HI, these data support our hypothesis that MgSO 4 induces CNS tolerance (i.e. confers preconditioning) rather than conferring direct protection during/after the insult.
Preconditioning with MgSO 4 does not change CBF
We then explored the possible mechanisms behind the profound preconditioning effect of MgSO 4 . It is wellknown that MgSO 4 has cerebrovascular effects, modulating the release of calcitonin gene-related peptide and nitric oxide, 39 and could theoretically improve CBF during HI, explaining its protective action. However, no significant difference in CBF could be detected between MgSO 4 and vehicle at 24 h after administration or during the subsequent period of HI (Figure 2(c) ), implying that MgSO 4 does not provide protection by affecting CBF.
MgSO 4 regulates mitochondrial/metabolic mRNA and miRNA in the brain
The development of CNS injury resistance required >12 h delay after MgSO 4 injection (Figure 1) . Previous studies have shown that preconditioning protection can depend on gene transcription and protein translation, 16 therefore we analyzed the effect of (Tables S3 and S4 ). Selective RT-PCR was performed to confirm differences observed by microarray, establishing that MgSO 4 indeed modulates gene expression (Figure 3(b) ). Using ClustVis, a PCA plot 40 was constructed using data from all 907 regulated genes at 24 h (Figure 3(c) ) showing a clear separation between samples from MgSO 4 pre-treated animals and vehicle offering further evidence that MgSO 4 affects gene transcription in the brain. Many of the regulated genes relate to mitochondrial function and at 24 h after MgSO 4 administration, both succinate dehydrogenase (SDH) and malate dehydrogenase were significantly downregulated (Figure 3(d) ). Furthermore, pathway analysis demonstrated that metabolic pathways were significantly downregulated at 24 h after MgSO 4 vs. vehicle (Z score: 2.98) which was further confirmed in the gene ontology analysis where 226/351 cellular metabolic process genes (Z score: 4.14) and 72/95 mitochondrial genes (Z score: 4.14) were downregulated (GeneSifter software, Geospiza). The gene data used for the PCA (above; 3(c)) was then used to create a heatmap showing up-or downregulation of multiple genes at 24 h after MgSO 4 treatment compared to vehicle (Figure 3(e) ). Heatmap clusters were constructed from all genes found to be regulated in metabolic pathways visualizing that 65% of genes in cellular metabolic processes (Figure 3(f) ) and 76% of mitochondria-related genes were downregulated ( Figure  3(g) ). We also performed analyses of corresponding proteins utilizing an experimental dataset from the proteomic study of about 7300 mitochondrial proteins from MitProNet 40, 41 (a functional linkage network of mitochondrial proteins generated by integrating genomic features encoded by a wide range of datasets including genomic context, gene expression profiles, protein-protein interactions, functional similarity and metabolic pathways). We superimposed our microarray data on MitoProtNet dataset and performed IPA analyses and found a significant down-regulation of genes corresponding to proteins in complexes I, II, III and IV of the ETC at 24 h by MgSO 4 (ANOVA; p < 0.05).
MgSO 4 targets pathological succinate accumulation in the immature brain
These results indicate that MgSO 4 modulates mitochondrial pathways, including succinate metabolism, which is interesting but not surprising as magnesium is involved in regulation of >600 enzymatic reactions including those involved in energy metabolism. 39, 42 However, recently Chouchani et al. 43 demonstrated that the extent of succinate increase during ischemia is critical as it triggers production of ROS and impairs mitochondrial function. Other groups 42 suggest that succinate triggers a pro-inflammatory response which could be critical during post-HI recovery. Therefore, we explored whether MgSO 4 modulates the metabolomic response before and during HI ( Figure S2 ). The analysis revealed that the MgSO 4 -treated samples differ from vehicle in the 3 h group for cortex (Figure 4(a) ), indicating that MgSO 4 itself has an effect on brain metabolism. Furthermore, MgSO 4 suppressed metabolic responses exacerbated in cerebral cortex during the HI insult. Succinate was significantly increased after HI in the vehicle-treated rats (n ¼ 9) (from 4.1 AE 0.5 a.u. to 11.6 AE 2.4 a.u.; p < 0.01), whereas no such increase was detected following MgSO 4 pretreatment (n ¼ 6) (from 4.2 AE 0.5 a.u. to 6.6 AE 2.0 a.u.; NS) (Figure 4(b) and (c) ). An increase in GABA in the cerebral cortex was detected in the vehicle-treated group (n ¼ 9) after 60 min of HI (from 2.3 AE 0.2 a.u. to 4.3 a.u.; p < 0.0001) whereas no increase was detected in the MgSO 4 group (n ¼ 6) (from 2.5 AE 0.3 a.u. to 2.5 AE 0.4 a.u.; NS). As expected, phosphocreatine and ATP/ADP levels decreased significantly in the vehicle group after HI (p < 0.0004 and p < 0.0001, respectively), whereas the levels were better maintained in the MgSO 4 group. Additionally, a significant difference in phosphocreatine (p < 0.03) and ATP/ADP (p < 0.03) concentration was detected between the vehicle and MgSO 4 pre-treated groups. Lactate was significantly increased in both the MgSO 4 (from 6.5 AE 0.6 a.u. to 30.2 AE 5.7 a.u.; p < 0.0001) (n ¼ 6) and vehicle group (from 6.1 AE 0.6 a.u. to 48.8 AE 8.0 a.u.; p < 0.0001) (n ¼ 9) although with a tendency towards being higher in the latter (NS). Glucose concentrations were lower after HI with no difference between groups (Figure 4(c) ). These metabolic data indicate that the potentially toxic succinate accumulation is attenuated by MgSO 4 pre-treatment and this effect was paralleled by preservation of high-energy phosphates indicating protection of mitochondrial function.
MgSO 4 preserves brain mitochondrial respiratory capacity
The Complex-I-mediated respiratory capacity of isolated brain mitochondria was analyzed using high-resolution respirometry (O2k chamber). No significant difference in RCR, i.e. STATE 3/STATE 4 respiration, was detected between MgSO 4 and vehicle at 24 h after injection ( Figure 5(a) and (c) ). We found, however, that the RCR decreased from 5.3 AE 0.5 pmol/(s*mg); n ¼ 7 to 2.7 AE 0.4 pmol/(s*mg); n ¼ 6; p < 0.002 after 30 min HI in the vehicle group, whereas it remained unchanged at 30 min HI in the MgSO 4 group (4.5 AE 0.2 pmol/ (s*mg); n ¼ 6 before HI and 4.4 AE 0.6 pmol/(s*mg) after 30 min HI; n ¼ 7) (Figure 5(b) and (c) ). Hence, the RCR was significantly higher in the MgSO 4 group compared with vehicle at 30 min HI induced 24 h after administration (p < 0.05).
To further characterize the effect of MgSO 4 on mitochondrial function, we studied Complex-II-mediated mitochondrial respiration using succinate and rotenone in the O2k. The results showed a significant increase in succinate-driven OXPHOS (S-OXPHOS) in the MgSO 4 pre-treated group compared to vehicle (p < 0.005) ( Figure 5 (e) and (f)) after 60 min HI. Further we analyzed the succinate driven ETS capacity (S-ETS) using the uncoupler FCCP to induce maximal Complex-II-mediated respiration, which was significantly higher in the MgSO 4 group (p < 0.005) (Figure 5(e) and (f) ). No significant increase could be detected in the Complex-II-mediated respiratory capacity after the addition of FCCP during these settings (compared to S-OXPHOS) which is in concordance with previous reports. 44 A significant difference was also detected in the basal mitochondrial respiration (STATE 1) between the MgSO 4 pre-treated group and vehicle (p < 0.009) as well as in STATE 2 respiration, (when ADP is added to mitochondria in the absence of reducing substrates) (p < 0.005, n ¼ 6/group) ( Figure 5(d) ). In summary, these data indicate that MgSO 4 preserves mitochondrial Complex-I and-II respiration after HI. MgSO 4 attenuates ROS production in the brain after HI Next, we investigated whether this functional improvement was associated with alleviation of oxidative stress. Production of ROS in isolated brain mitochondria was measured using Amplex Red. We found that the Complex-I-linked production of ROS tended to decrease in the MgSO 4 samples (n ¼ 4) at 30 min HI compared to vehicle (n ¼ 5) in the presence of NADH generating substrates (pyruvate, glutamate and malate) (Figure 6(a) ) as well as when FCCP had been added (N-ETS) (Figure 6(b) ). Furthermore, the production of ROS was measured using the O2k in the absence of exogenous NADH generating substrates with the purpose of detecting endogenous ROS production only. When succinate was added to the isolated brain mitochondria stimulated with ADP, the detected production of ROS was 0.004 AE 0.001 pmol/(s*mg); n ¼ 6 in vehicle vs. 0.002 AE 0.001 pmol/(s*mg) (n ¼ 6) in the MgSO 4 group. Following the addition of FCCP, a significantly higher production of ROS was detected in the vehicle group (0.004 AE 0.001 pmol/ (s*mg); n ¼ 6) compared with the MgSO 4 group (0.002 AE 0.0001 pmol/(s*mg); n ¼ 6) (Figure 6 ( Figure 6(d) ) corresponding to our findings using the O2k equipment.
MgSO 4 pre-treatment attenuates the post HI accumulation of chemokines and pro-inflammatory cytokines
Previous studies suggest that succinate activates the succinate receptor 1 (SUCNR1) leading to activation of pro-inflammatory responses via p38, NFAT (nuclear factor of activated T-cells) and NFkB (nuclear factor kappa B) signaling. 42 Therefore, we speculated that MgSO 4 could modify the cytokine/chemokine responses after HI due to the attenuation of succinate accumulation (above). Furthermore, mitochondrial ROS production has been suggested to enhance the pro-inflammatory response 42 and as MgSO 4 reduced ROS production, we expected that the inflammatory response would be affected. We prepared whole brain homogenate at 6 and 24 h after HI comparing the 
Discussion
We have demonstrated for the first time that MgSO 4 conferred preconditioning to the immature rat brain if given 6 days-12 h prior to an HI or excitotoxic insult reducing brain injury in all areas, particularly cerebral cortex, by as much as 80%. Administration of MgSO 4 induced mRNA/miRNA changes in the cerebral cortex previously shown to be regulated in response to other forms of preconditioning and many of them related to mitochondria. [45] [46] [47] [48] Metabolic pathways were generally downregulated including mitochondrial network genes, especially those corresponding to proteins in the electron transport chain. The metabolome was significantly modulated in both serum and brain at 3 h after MgSO 4 . Succinate accumulation, mitochondrial functional deterioration during HI and the increase of mitochondrial ROS production and tissue cytokines/chemokines after the insult were all attenuated by pre-treatment with MgSO 4 .
MgSO 4 was given as an intraperitoneal bolus causing a temporary increase in serum magnesium concentration to $3.3 mmol/L at 3 h but it is important to point out that the levels were completely normalized at 24 h post injection, i.e. the concentration of magnesium was at physiological levels during and after the HI insult. According to previous studies, increases of serum MgSO 4 elevate magnesium concentrations in the brain tissue 49 as well as in the cerebrospinal fluid 50 suggesting that extracellular and intracellular magnesium concentrations increase at least transiently in the brain. Magnesium modulates calcium hemostasis and the activity of multiple enzymes 51 possibly explaining why the metabolome is altered in blood and brain at 3 h after MgSO 4 administration. These metabolic/ enzymatic changes may secondarily induce the subtle gene transcription changes detected in the brain at 3 and 24 h after treatment, probably contributing to development of mitochondrial and CNS resistance as well as the metabolism downregulation and attenuation of succinate accumulation in response to HI. Indeed, the gene ontogeny and pathway analysis indicating metabolic suppression by MgSO 4 are supported by a recent clinical study demonstrating a drop in cerebral oxygen consumption and cerebral oxygen extraction in newborns pre-exposed to MgSO 4 antenatally. 52 These changes occurred in spite of unaffected CBF 52 which agrees with our results showing that CBF was not different between the MgSO 4 and vehicle group at 24 h after administration or even during the subsequent HI, supporting that both groups were suffering from a similar degree of primary HI insult.
Succinate is reported to accumulate in tissues, including the immature and adult brain, 53, 54 in response to HI leading to succinate-driven excessive mitochondrial production of ROS during reperfusion and subsequent aggravation of injury. 51 The cause of the succinate increase is reversal of SDH activity, resulting in the conversion of fumarate to succinate, driven by fumarate overflow from purine nucleotide breakdown and partial reversal of the malate/aspartate shuttle. 51 The SDH inhibitor dimethyl malonate prevents accumulation of succinate and ROS, conferring significant neuroprotection. 53 Presently, we found that MgSO 4 pre-treatment prevented the accumulation of succinate and improved mitochondrial function in the neonatal brain. Interestingly, the mRNA analysis of the rat brain tissue demonstrated that the genes for SDH and malate dehydrogenase were downregulated by MgSO 4 . When analyzing Complex-II-mediated succinate-driven respiration in isolated mitochondria, we detected an increase in the MgSO 4 pre-treated group, whereas no such increase was detected in the vehicle group, further confirming our data on endogenous succinate accumulation in the vehicle group. GABA accumulation during HI was also attenuated by MgSO 4 . Speculatively, magnesium modulates both the reversal of SDH and the GABA-shunt, thereby preventing accumulation of toxic levels of succinate in the brain tissue after HI. Succinate accumulation during HI can also trigger a more profound inflammation 42, 55 during the secondary phase after HI which may worsen brain injury. 1 In fact, several studies show that MgSO 4 attenuates the pro-inflammatory reaction in experimental models. 56, 57 Additional experiments are needed to clarify the mechanisms behind succinate accumulation in the immature brain and to elucidate how these metabolic events and mitochondrial functions are modulated by magnesium preconditioning as well as their specific role in neuroprotection.
Many enzymes in intermediary metabolism are modulated by magnesium, affecting >600 biological reactions 51 which could hypothetically shift the balance and attenuate succinate accumulation. Indeed, we found that genes related to proteins in the ETC were downregulated by MgSO 4 which has been shown to occur also in preconditioning of the heart in parallel to improvement of mitochondrial respiratory recovery. 48 Recently, it was discovered that when preventing degradation of components of the ETC, such as SDH, BAX dependent apoptotic cell death known to be critical in HI brain injury, 58 was attenuated. 59 This study offers mechanistic information indicating that succinate metabolism and mitochondrial function are involved in preconditioning by MgSO 4 . However, more detailed information (using 1 H-NMR, 31 P-NMR and 13 C-NMR) on how the metabolic network is modulated by MgSO 4 treatment is needed, having to be addressed in the future.
Concerning clinical implications, the present finding that a transient increase of serum MgSO 4 induces tolerance in the developing brain rather than providing a direct neuroprotective effect during/after the insult is of great importance. Indeed, these data support the clinical findings that MgSO 4 is an effective neuroprophylaxis if treatment starts antenatally, some-time before the critical period for brain insults during delivery and the first few days of life. However, our results also indicate that it may be sufficient to offer a MgSO 4 bolus (high enough to reach a transient magnesium increase to >2.5 mmol/ l which in most patients would correspond to 6 g of MgSO 4 ) rather than administration of MgSO 4 infusions during delivery up until birth. Today there is no consensus as to required MgSO 4 dose/duration for neuroprophylaxis as all published randomized trials have followed different dosing regimens. [10] [11] [12] [13] Some studies even indicate that long-lasting infusions of MgSO 4 may increase necrotizing colitis, gut perforations and perinatal mortality, [60] [61] [62] problems that could be avoided by administration of only a bolus. In addition, MgSO 4 infusions require much more extensive monitoring of the mother than if only a bolus dose is provided which affects compliance for clinical implementation. Therefore, clinical studies are warranted to investigate whether providing only a bolus of MgSO 4 is an efficient mode of neuroprophylaxis with superior safety and compliance in women in preterm labor.
Furthermore, the understanding that MgSO 4 induced preconditioning protection of the immature CNS could lead to development of prophylactic treatment of other patients at high risk such as cases with high risk of intrapartum asphyxia or cases undergoing open heart surgery.
In conclusion, MgSO 4 induces strong preconditioning of the immature brain which provides resistance to HI-and excitotoxicity-mediated injury in rats and mice. Magnesium increases in the CNS and have previously been shown to modulate enzymatic activities, calcium homeostasis and NMDA receptor activity. These alterations are anticipated to provoke transcriptomal changes with modulation of neuroprotective and metabolic mRNAs and miRNAs. The metabolism will be downregulated and altered leading to reduced succinate toxicity, mitochondrial protection and slower loss of high energy phosphate reserves in the brain tissue after HI. Speculatively, these reactions contribute to attenuated ROS production and inflammation ( Figure S3 ).
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